Entering text into the input field will update the search result below

BioCryst's IV flu drug Alpivab OK'd in Europe

  • BioCryst Pharmaceuticals (NASDAQ:BCRX) announces that the European Medicines Agency (EMA) has approved ALPIVAB (peramivir), a single intravenous (IV) infusion for the treatment of uncomplicated influenza in patients at least two years old.
  • The company says the approval triggers a $5M milestone payment from licensee Seqirus, although it adds that the two companies are currently involved in a dispute over certain claims in their contract.

Recommended For You

About BCRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BCRX--
BioCryst Pharmaceuticals, Inc.